MO987IMPACT OF POST-TRANSPLANT TUBERCULOSIS ON LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS: RISK FACTORS AND OUTCOME
Authors: Elshahat Samar , El wasif Salwa , Omar Essam Lotfy , Al-Barshomy Said M 
Published: May 2021

Abstract

Background and Aims
TB is encountered worldwide more frequently among renal transplant recipients due to of the state of immunosuppression. Antituberculosis drugs cause CYP-450 enzyme induction that increase the metabolism of CNI and mTORi So, decreasing the plasma trough level which in turn expose the transplant recipient to the risk of rejection. Our study concerned with the impact of post-transplant TB on live donor kidney transplant recipients outcome.

Method
This is retrospective cohort study held in Urology and Nephrology Center, Mansoura University, Egypt. The study included 210 patients out of 3200 kidney transplant recipients (KTRs) who underwent renal transplantation at Mansoura urology and Nephrology Centre between March 1976 and December 2019. The patients were divided into 2 main groups according to history of post-transplant tuberculosis, a group of 70 kidney transplant recipients who developed tuberculosis after transplantation served as a study group and a matched group of 140 kidney transplant recipients who did not develop tuberculosis after transplantation served as control group. Study group was then subdivided into pulmonary and urinary TB groups.

Results
We found that patients with Low BMI are associated with higher incidence of post-transplant TB (p value: 0.023). While, post-transplant TB was associated with increased incidence of post-transplant DM, bacterial infection, CMV infection and surgical wound infection.
Exposure to rejection episodes (either acute or chronic) is comparable among both groups. Post-transplant diabetes incidence was higher among TB group with statistical significant difference (p value: 0.01). Bacterial infection incidence including pneumonia, urinary tract infection and gastroenteritis were associated with higher incidence of TB with statistically significant difference (p value: 0.012). CMV infection incidence was significantly higher among TB group (p value: 0.02). Incidence of wound infection post-transplantation was higher among TB group with statistically significant difference (p value: 0.014). Both groups were comparable regarding creatinine and creatinine clearance at last follow-up (p value: 0.61, 0.51 respectively). Overall, there was no statistically significant difference among both groups regarding 5, 10 and 15 years graft and patient survival (p value: 0.54, 0.15 respectively). During treatment of TB in the study group, there was statistical significant difference regarding liver enzymes and CNI doses either before or during anti-tuberculous treatment as liver enzymes were elevated (p value: 0.023) and higher doses of CNI were required to achieve satisfactory trough level during antituberculus treatment (p value: 0.037). Liver enzymes dropped significantly and lower doses of CNI were used after cessation of anti-tuberculous treatment (p value: 0.041, 0.03 respectively). Study group was then subdivided into 2 main groups: pulmonary TB (42 KTRs) and Urinary TB (28 KTRs). There was no statistical significant difference among both groups regarding baseline data, transplantation data, post-transplant medical complication except that CMV infection incidence was higher among pulmonary TB group (p value: 0.012). Patient and graft survival were comparable.

Conclusion
Among renal transplant recipients, tuberculosis is a serious problem for both the disease itself and its treatment with anti-tuberculous medications. In our series the rejection was comparable in both groups (with or without tuberculosis) this may be explained by frequent monitoring of the immunosuppressive drug level.